Hims&Hers为某些专业人员提供每月仅99美元的复合糖尿病和减肥药物-动脉网

Hims & Hers To Offer Access To Compounded Diabetes And Weight Loss Drugs For Just $99/Month To Certain Professional Personnel

benzinga 等信源发布 2024-09-19 12:50



可切换为仅中文







On Wednesday, Hims & Hers Health, Inc. HIMS launched the Service Appreciation Initiative, offering compounded GLP-1 weight loss medications to some personnel for as low as $99 per month.

周三，Hims&Hers Health，Inc。Hims启动了服务增值计划，向一些人员提供复合GLP-1减肥药物，每月最低价格为99美元。

The initiative covers eligible U.S. military personnel, veterans, teachers, nurses, and first responders.

该计划涵盖符合条件的美国军人、退伍军人、教师、护士和急救人员。

Hims & Hers Health is a telehealth company known for offering compounded alternatives to popular GLP-1 weight-loss treatments. Its shares have soared over 120% since August 2023.

Hims＆Hers Health是一家远程保健公司，以提供流行的GLP-1减肥疗法的复合替代品而闻名。自2023年8月以来，其股价已飙升逾120%。

Also Read: Battle Over Compounded Weight-Loss Medications – Sustainability and Regulation

另请阅读：对抗复合减肥药物-可持续性和监管

The platform has already seen success, with over 12,000 customers reporting significant weight loss—an average of 10.2 pounds with compounded GLP-1 injections and 6.3 pounds with non-GLP-1 oral medications—within four weeks of starting treatment.

该平台已经取得了成功，超过12000名客户报告说，在开始治疗的四周内，复合GLP-1注射平均体重减轻了10.2磅，非GLP-1口服药物平均体重减轻了6.3磅。

The issue of obesity is particularly significant in service roles. Studies have shown that around 70% of American adults are overweight or obese, and the rates are alarmingly high among veterans, military personnel, teachers, nurses, police officers, and firefighters.

肥胖问题在服务角色中尤为重要。研究表明，大约70%的美国成年人超重或肥胖，退伍军人、军人、教师、护士、警察和消防员的肥胖率高得惊人。

Stress, sleep disruption, and other occupational hazards contribute to these statistics, making the need for affordable weight loss solutions even more urgent.

压力、睡眠中断和其他职业危害导致了这些统计数据，使得对负担得起的减肥解决方案的需求更加迫切。

Novo Nordisk A/S NVO CEO Lars Fruergaard Jørgensen has defended the high U.S. prices of the company's blockbuster drugs, Ozempic and Wegovy, stating that these medications are reducing the economic burden of obesity-related health issues.

诺和诺德公司（Novo Nordisk A/S NVO）首席执行官拉尔斯·弗鲁尔加德·约根森（Lars Fruergaard Jørgensen）为该公司的畅销药奥森匹克（Ozempic）和韦戈维（Wegovy）在美国的高价进行了辩护，称这些药物正在减轻肥胖相关健康问题的经济负担。

Earlier this year, a study revealed that Ozempic could be produced for less than $5 a month, starkly contrasting its current monthly price of $968.52. Similarly, Wegovy is priced at $1,349.02 per month.

今年早些时候，一项研究显示，Ozempic的月售价可能不到5美元，与目前968.52美元的月售价形成鲜明对比。同样，Wegovy的价格为每月1349.02美元。

Senator Bernie Sanders, chair of the Health, Education, Labor and Pensions (HELP) Committee, has been vocal about the stark price differences for Ozempic and Wegovy between the U.S. and other countries.

健康、教育、劳工和养老金（HELP）委员会主席、参议员伯尼·桑德斯（BernieSanders）就Ozempic和Wegovy在美国与其他国家之间的巨大价格差异发表了言论。

Novo Nordisk CEO Lars Jorgensen is scheduled to appear before the Senate HELP Committee, led by Chairman Bernie Sanders, for a hearing next week that will focus on hearing popular drugs, Ozempic, and Wegovy in the U.S.

诺和诺德首席执行官拉尔斯·约根森（LarsJorgensen）计划出席由主席伯尼·桑德斯（BernieSanders）领导的参议院帮助委员会下周举行的听证会，该听证会将重点关注美国流行药物、奥森匹克（Ozempic）和韦戈维（Wegovy）的听证会。

Price Action: HIMS stock is up 3.49% at $16.88 at last check Thursday.

价格走势：HIMS股价周四上涨3.49%，至16.88美元。